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Abstract 
Vaccines contain residual DNA derived from the cells used to produce them. As part of our 
investigation to assess the risk of this cellular DNA, we are developing a quantitative in vivo 
assay to assess the oncogenicity of DNA. In an earlier study, we had generated expression 
plasmids for two oncogenes – human activated T24-H-ras and murine c-myc – and had 
shown that these two plasmids, pMSV-T24-H-ras and pMSV-c-myc, could act in concert to 
induce tumors in mice, although the efficiency was low. In this study, we took two ap-
proaches to increase the oncogenic efficiency: 1) both oncogene-expression cassettes were 
placed on the same plasmid; 2) transfection facilitators, which increase DNA uptake and 
expression in vitro, were tested. The dual-expression plasmid, pMSV-T24-H-ras/MSV-c-myc, is 
about 20-fold more efficient at tumor induction in newborn NIH Swiss mice than the sepa-
rate expression plasmids, with tumors being induced with 1 µg of the dual-expression plas-
mid DNA. However, none of the transfection facilitators tested increased the efficiency of 
tumor induction. Based on these data, the dual-expression plasmid 
pMSV-T24-H-ras/MSV-c-myc will be used as the positive control to develop a sensitive and 
quantitative animal assay that can be used to assess the oncogenic activity of DNA.   
Key words: H-ras, c-myc, oncogenes 
Introduction 
Because all viral vaccines contain some residual 
DNA from the cell substrate used to produce them, it 
is important to establish whether this DNA could 
pose a risk to vaccine recipients and, if so, to quantify 
the risk. The issue of the potential oncogenic risk 
posed by DNA was one of the reasons that the Armed 
Forces Epidemiological Board recommendation in 
1954 against the use of tumorigenic cells, or cells de-
rived from human tumors, for the manufacture of 
vaccines for human use [1, 2]. This recommendation 
remained in effect for over 40 years. However, opi-
nions on the risk posed by residual cellular DNA have 
varied from there being no risk to it being considered 
to be an important risk factor [3-5], particularly for Int. J. Biol. Sci. 2010, 6 
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vaccines manufactured in cells that are tumorigenic or 
are derived from tumors. The potential risk from cel-
lular DNA arises both from its oncogenic activity and 
from the possibility that the DNA could encode infec-
tious agents [6]. Studies on DNA infectivity has been 
presented elsewhere (Sheng-Fowler et al., in press). 
 The possibility that vaccines produced in neop-
lastic cells might have the capacity to induce a neop-
lastic phenotype in the cells of vaccine recipients 
through the injection and uptake of residual DNA 
from the neoplastic cell substrate is supported by the 
presence of oncogenes in the genomes of eukaryotic 
cells [7] and the demonstration that these cellular on-
cogenes can transform primary cells in culture [8-10] 
into cells that can become tumorigenic in animals [8, 
11]. Another mechanism by which residual cellular 
DNA could induce oncogenesis would be through the 
integration of the DNA into t h e gen o m e o f  c el ls  o f  
vaccine recipients. Integration of residual cellular 
DNA could potentially activate a dominant cellular 
oncogene or inactivate a tumor suppressor gene. 
However, oncogenesis through integration of DNA 
has been considered to be unlikely, because integra-
tion of exogenous DNA per se is a low probability 
event [12] and the probability of integration at a par-
ticular site is even lower [13-18] (Sheng-Fowler et al., 
in press). Oncogenesis through the inactivation of a 
cellular tumor-suppressor gene would be even less 
likely, because both alleles of the suppressor gene 
would have to be inactivated. Therefore, the major 
oncogenic risk of DNA in vaccines would be through 
the introduction of a dominant activated oncogene 
whose expression either could directly transform a 
cell in a vaccinated individual into a cell that could 
form a tumor [8-10], or could cause the “initiation” of 
the tumorigenic process that, with the acquisition of 
additional mutations over time, could lead to the de-
velopment of a tumor [19-22].  
  It has been estimated that the genomes of nor-
mal mammalian cells have more than 200 pro-
to-oncogenes [23], although, in normal cells, these 
proto-oncogenes have not been activated to become 
dominant transforming genes. However, for several 
reasons, this number is likely an underestimate. For 
example, ordinary housekeeping genes such as 
phosphoglycerate mutase [24] and certain cellular 
receptors such as the constant gamma chain of the 
IL-2 receptor [25] have been shown to be capable of 
becoming transforming oncogenes. In addition, it has 
recently been demonstrated that certain microRNA 
(miRNA) genes can induce a polyclonal B-cell malig-
n a n c y  i n  t r a n s g e n i c  m i c e  [ 2 6 ] ,  a n d  s o m e  o f  t h e s e  
miRNAs have been implicated in human cancer 
[27-31], thus expanding the number of genes in cellu-
lar DNA that have the potential to become dominant 
oncogenes.  
  Because few studies had attempted to measure 
DNA oncogenicity in vivo, we undertook to develop 
an animal model that could be used to estimate the 
oncogenic potential of various DNAs. In a previous 
study, we generated expression plasmids for the ac-
tivated human T24 H-ras gene and for the murine 
c-myc gene [32]. These oncogenes were initially cho-
sen, because they had been shown to transform ro-
dent cells in vitro into cells that were tumorigenic in 
vivo [8, 33, 34]. Our initial studies demonstrated that 
these plasmids were oncogenic in vivo in two mouse 
s t r a i n s .  W e  f o u n d  t h a t  N I H  S w i s s  m i c e  w e r e  m o r e  
sensitive to oncogenic DNA than C57BL/6, and 
newborn mice were more sensitive than adult mice. 
Both oncogenes were required for tumor induction, 
and tumors were only induced by the highest 
amounts of DNA used (12.5 µg of each plasmid). In 
this assay, a ten-fold dilution of the DNA showed no 
activity [32]; this was likely due to a requirement that 
both oncogenes be taken up by the same cell.  
 In the current study, we took two approaches to 
increase the efficiency of tumor induction by onco-
genic DNA. In the first, we generated dual-expression 
plasmids that contained both the human T24-H-ras 
and mouse c-myc oncogenes and expressed each gene 
from its own promoter. In the second, we evaluated 
whether transfection facilitators, reagents that in-
crease DNA uptake and expression in vitro, were able 
to enhance the efficiency of tumor induction by DNA 
in vivo.  
 The results showed that having both oncogenes 
on the same molecule increased the efficiency of tu-
mor induction. As little as 1 µg of the dual-expression 
plasmid (pMSV-T24-H-ras/MSV-c-myc) DNA was 
able to induce tumors in newborn mice. However, 
none of the transfection facilitators increased the on-
cogenic efficiency of the dual-expression plasmid in 
mice. The dual-expression plasmid 
pMSV-T24-H-ras/MSV-c-myc will be the positive 
control oncogenic DNA that will be used to establish a 
sensitive and quantitative in vivo assay for DNA on-
cogenesis. Once this assay is established, it will be 
used to estimate the oncogenic risk of cellular DNA in 
vaccines and other biological products. In addition, an 
assay that can detect the oncogenic activity of DNA 
introduced directly into mice could also be used to 
evaluate the in vivo oncogenic potential of cellular or 
viral oncogenes, thus circumventing the indirect ap-
proach of generating cell lines expressing these on-
cogenes and then assessing the tumorigenicity of 
these cells in vivo.  Int. J. Biol. Sci. 2010, 6 
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Materials and Methods 
Construction of oncogene expression plasmids 
  The expression plasmids pMSV-T24-H-ras and 
pMSV-c-myc [32] were digested with NruI, and the 
oncogene-containing fragments were purified by gel 
electrophoresis. The vector pLS3 [32], which has sin-
gle sites for EcoRI, NruI, SacI, KpnI, SalI, PstI, PvuII, 
NotI, XbaI, AvrII BamHI, SpeI, NdeI, ClaI, BglII, HpaI, 
XhoI, SphI, BstBI, MluI, NcoI, NheI, and HindIII, was 
digested with NruI and separately with HpaI. After 
dephosphorylation with Antarctic phosphatase (New 
England BioLabs, Ipswich, MA), the vectors were pu-
rified by gel electrophoresis. The oncogene-containing 
NruI fragments were ligated both to NruI-digested 
pLS3 vector and to HpaI-digested pLS3. Those plas-
mids that contained either T24-H-ras or c-myc inser-
tions at the HpaI site were digested with NruI for in-
sertion of the other oncogene, and those plasmids that 
contained either T24-H-ras or c-myc insertions at the 
NruI site were digested with HpaI for insertion of the 
other oncogene. Of the eight possible dual-oncogene 
plasmid configurations, six were obtained (Fig. 1). 
Despite each plasmid having four long terminal re-
peat (LTR) elements in various orientations, all were 
stable to propagation in bacteria. Plasmid DNA was 
prepared as described [32]. 
 
 
Fig.1. Structures of six configurations of the dual expression plasmid pMSV-T24-H-ras/MSV-c-myc.  
 
 
Cell lines and cell culture 
The NIH 3T3 cells (CRL-1658) were obtained 
from the American Type Culture Collection (Manas-
sas, VA) and Rat-1 cells were originally obtained from 
Bill Topp (Cold Spring Harbor Laboratory). They 
were grown in Dulbecco’s modified Eagle’s medium 
(DMEM) supplemented with 1% glutamine and either 
5% fetal bovine serum (FBS; DMEM-5) for NIH-3T3 
cells or 10% FBS (DMEM-10) for Rat-1 cells.  
Transfection reagents  
 Transfection  facilitators were: PolyFect, Super-
Fect and Effectene (Qiagen Inc., Valencia, CA); Lipo-
fectamine and DMRIE-C (Invitrogen, Inc., Carlsbad, 
CA); DOTAP, DOSPER, and FuGene HD (Roche Ap-
plied Sciences, Indianapolis, IN); Transfectol (Gene-
Choice, Frederick, MD); aurintricarboxylic acid (Sig-
ma, St. Louis, MO); and in vivo-JetPEI (PolyPlus 
Transfection Inc., New York, NY).  
Animals and procedures 
  NIH Swiss mice were purchased from the Na-
tional Cancer Institute, Division of Cancer Treatment, 
Frederick, MD. Three of the dual-expression plasmids Int. J. Biol. Sci. 2010, 6 
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were selected for testing in animals – 2604-10, 2605-6a, 
and 2606-18 (Fig. 1).  
  Plasmid DNA in PBS (total volume 50 µL) was 
inoculated via the subcutaneous route above the sca-
pulae in both adult (two to four months of age) and 
newborn (one to two days of age) NIH Swiss mice 
using a 26-gauge needle and a 0.5 mL syringe. DNA 
amounts are indicated in the text; the total amount of 
DNA was made up to a constant amount by the addi-
tion of appropriate quantities of the empty expression 
vector pMSV/LS [32]. Animals were housed in cages 
with food and water ad libitum and a 12-hour 
light/dark cycle. Protocols were approved by the 
CBER Animal Use and Care Committees. Processing 
of tumors was done as described [32].  
Establishment of cell lines from tumors 
 Cell lines were established from tumor tissue as 
described using trypsin dispersal of the cells [32]. Cell 
lines were expanded in DMEM-10 and frozen as de-
scribed [32].  
Extraction of DNA from cell lines 
  Cells from the tumor-cell lines were harvested 
from T150 tissue-culture flasks by trypsinization and 
were washed in PBS. Between 2 x 107 and 1 x 108 cells 
(1 to 4 flasks depending on the cell line) were used to 
extract genomic DNA by the Qiagen Blood and Cell 
Culture DNA kit (Qiagen Inc., Valencia, CA).  
PCR analysis 
  Genomic DNA was subjected to PCR using 
primers that were designed to detect the plas-
mid-encoded oncogenes while not reacting with the 
endogenous genes [32]. PCR analysis was done with 
300 ng of genomic DNA (cell line or tumor) or 200 pg 
of plasmid DNA. A negative control was performed 
by omitting DNA (genomic DNA or plasmid). PCR 
products (2 µL of the 50 µL reaction) were resolved by 
electrophoresis on a 1.8% agarose gel containing 
0.025% ethidium bromide. Gels were photographed 
using an AlphaImager 3400 (Alpha Innotech, San 
Leandro, CA).  
Southern DNA analysis 
 Genomic DNA (50 µg) from the tumor-cell lines 
was digested with restriction enzymes and analyzed 
for complete digestion by analytical agarose-gel elec-
trophoresis. For Southern analysis, 8 µg of each di-
gested DNA were fractionated on a 1% agarose gel. 
After photographing, the gel was gently shaken at 
room temperature for 15 min in 0.25 N HCl to par-
tially depurinate the DNA. The gel was then neutra-
lized in 0.4 N NaOH for 30 min, and the DNA was 
transferred for 3 h by downward capillary action to 
Amersham Hybond-N+ membrane (GE Healthcare, 
Piscataway, NJ) in the same buffer using the 
Schleicher and Schuell TurboBlotter (Whatman Inc., 
Florham Park, NJ 07932). The DNA was cross-linked 
to the wet membrane using a UV Stratalinker 1800 
(Stratagene, La Jolla, CA) with 70 mJoules/cm2 of 
energy. The dried membranes were stored between 
two filter papers in plastic bags at 23–25°C. 
  Prehybridization and hybridization were done 
in glass roller bottles using a Hybaid Maxi 14 incu-
bator. Membranes were prehybridized in 10 mL of 
PERFECTHYB PLUS (Sigma, St. Louis, MO) at 68°C 
for 1 – 2 h. Probes were the gel-purified ras or myc 
genes (excised from the expression plasmids using 
NotI plus BamHI digestion) labeled using the 
North2South Biotin Random Prime Kit (Pierce, 
Rockford, IL). Probes (50 ng/mL) were added to the 
prehybridization solution, and the membranes were 
hybridized overnight at 68°C in glass cylinders. 
Membranes were washed once in 2 x SSC, pH 7.2, 
0.1% SDS for 30 min at room temperature, twice in 0.5 
x SSC, pH 7.2, 0.1% SDS for 30 min each time at 68°C, 
and once in 0.1 x SSC, pH 7.2, 0.1% SDS for 30 min at 
68°C.  
  Probe detection was done according to the 
manufacturer’s protocol (Pierce, Rockford, IL). Brief-
ly, the membrane was incubated in blocking buffer 
with shaking for 15 min at room temperature and then 
in fresh blocking buffer with the Stabilized Streptavi-
din-Horseradish Peroxidase Conjugate for another 15 
min at room temperature with shaking. The mem-
brane was washed with 1 x wash solution 5 times for 5 
min each time and incubated in substrate equilibra-
tion buffer for 5 min with gentle shaking followed by 
addition of the chemiluminescent substrate working 
solution buffer for 5 min without shaking. The mem-
branes were exposed to X-ray film for times varying 
for a few seconds to several minutes.  
Preparation of cell lysates and western blot 
analysis 
 This was done as described by Sheng et al. [32].  
Results 
Development of the dual-expression plasmids 
 Our previous studies had demonstrated that ac-
tivated human H-ras and murine c-myc could coope-
rate to induce tumors in immune-competent adult 
and newborn mice. Newborn mice were more sensi-
tive than adults and NIH Swiss mice were more sus-
ceptible than C57BL/6 mice [32]. However, the effi-
ciency of tumor induction was low: 12.5 µg of each of 
the plasmids pMSV-T24-H-ras and pMSV-c-myc were 
required for tumor induction. Because tumor induc-Int. J. Biol. Sci. 2010, 6 
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tion required that a single cell take up both plasmids, 
i t  w a s  r e a s o n a b l e  t o  e x p e c t  t h a t  h a v i n g  b o t h  o n c o -
genes on the same plasmid would increase the effi-
ciency of tumor induction.  
  The two oncogene-expression cassettes were 
combined in the plasmid pLS3 (the steps are outlined 
in Materials and Methods). Of the eight possible ar-
rangements of the two oncogenes, six were obtained 
(Fig. 1). These plasmids differed in the orientation of 
the oncogene-expression cassette and the position of 
the ras and the myc genes relative to each other. Be-
cause each gene is expressed from its own murine 
sarcoma virus (MSV) long terminal repeat (LTR) 
promoter and has its own termination signal, we ex-
pected that the arrangement of the oncogenes in the 
plasmid would not affect the oncogenic activity of the 
plasmids. Despite the presence of four MSV LTR 
elements in various orientations, all of the plasmids 
were stable when propagated in bacteria.  
 Each of the dual-expression plasmids was tested 
in vitro for its capacity to induce loss of contact inhi-
bition in a focus-formation assay in both NIH 3T3 cells 
and Rat-1 cells. All six versions of 
pMSV-T24-H-ras/pMSV-c-myc induced foci in both 
cell lines and had indistinguishable activities (data not 
shown). Three were chosen – 2604-10, 2605-6a, and 
2606-18 – to assess their ability to induce tumors in 
vivo.  
Activity in newborn and adult NIH Swiss mice 
 Four doses (20 µg, 10 µg, 5 µg, and 1 µg) of the 
three versions of the dual-expression plasmid 
pMSV-T24-H-ras/MSV-c-myc were inoculated sub-
cutaneously into both adult and newborn NIH Swiss 
mice. Animals were monitored daily for general 
health and twice weekly for tumor formation. Tumors 
began to appear after about 4 weeks, and no addi-
tional tumors were found after about nine weeks. The 
newborn mouse was more sensitive than the adult 
mouse to tumor induction by DNA. This is shown by 
the combined number of mice with tumors at all doses 
of DNA. For example, tumors were induced in 8 out 
of 59 (13.5%) adult mice and in 18 out of 54 (35%) 
newborn mice (Table 1). The newborn mouse was also 
more sensitive to tumor induction by lower doses of 
DNA: 1 µg of DNA caused tumors in newborn mice, 
whereas no tumors were induced in adult mice with 
less than 5 µg of DNA.  
  From the results of Table 1, there was no clear 
dose-response relationship with any one group. It is 
likely that this is a consequence of the low numbers of 
animals used and of the variation commonly seen is 
animal experiments. Additional experiments are 
planned to investigate this variability.  
 
 
Table 1. Tumor induction in adult and newborn NIH Swiss Mice by three variants of the dual expression plasmid. 
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PCR analysis of the DNA from tumor-cell lines 
  Cell lines were established from five of the tu-
mors induced in adult mice (D003-A, D003-F, D003-I, 
D003-J, D003-E) and from four of the tumors induced 
in newborn mice (D004-B. D004-F, D004-I, D004-K). 
To determine whether the tumors were induced by 
the inoculated oncogenes, DNA was extracted from 
the cell lines, and PCR was carried out using primers 
that were selective for the exogenous H-ras and c-myc 
genes and would not amplify the endogenous genes 
[32].  
  
 
Fig. 2. PCR analysis of DNA isolated from cell lines estab-
lished from tumors induced by the dual-expression plas-
mids (pMSV-T24-H-ras/MSV-c-myc) in adult NIH Swiss 
mice. DNA from the tumor cell lines was amplified by PCR 
using Oligos610/511 for the 5' myc gene and Oligos513/515 
for the 3' myc gene and Oligos509/512 for the 5' ras gene 
and Oligos514/515 for the 3' ras gene. The PCR products 
were resolved by electrophoresis in a 1.8% agarose gel. A. 
The 5' myc and 3' myc gene. B. The 5' ras and 3' ras gene. 
Lanes M; marker; lanes a: no DNA control; lanes b: positive 
controls pMSV-T24-H-ras or pMSV-c-myc; lanes c: D003-A; 
lanes d: D003-F; lanes e: D003-I; lanes f: D003-J; lanes g: 
D003-E.  
 
PCR analysis of the cell lines established from 
t u m o r s  i n d u c e d  i n  a d u l t  m i c e  r e v e a l e d  t h a t  D N A  
from three out of the five lines (D003-A, D003-I, 
D003-J) produced PCR products that co-migrated 
with the products amplified from the control plas-
mids with both the 5' and 3' primer sets for both the 
c-myc and H-ras genes (Fig. 2A and B; lanes c, e, and f). 
DNA from the other two lines (D003-F, D003-E) either 
failed to yield the expected PCR product with both of 
the myc primer sets (D003-F)(Fig. 2A; lane d) or only 
yielded the expected product with the 5' myc primer 
set (D003-E)(Fig. 2A; lane g). DNA from these same 
two lines did not yield the expected ras gene PCR 
product with either the 5' or the 3' ras primers (Fig. 2B; 
lanes d and g).  
  The most likely reason for the absence of onco-
gene DNA in these two cell lines was that the tumor 
cells were selectively lost during the establishment of 
these cell lines from the tumors, possibly as a conse-
quence of over digestion with the trypsin used to 
disperse the tumor tissue. If this explanation were 
correct, then DNA isolated directly from the tumor 
would be expected to carry the 
pMSV-T24-H-ras/pMSV-c-myc sequences. As shown 
in Fig. 3, PCR analysis of DNA isolated from tumors 
D003-E and D003-F were positive with both the 5' and 
3' myc primers (Fig. 3A, lanes d and f, respectively) 
and with both the 5' and 3' ras primers (Fig. 3B, lanes d 
and f, respectively).  
 
 
Fig. 3. PCR analysis of DNA isolated from tumors and 
from cell lines established from the tumors induced by the 
dual-expression plasmids (pMSV-T24-H-ras/MSV-c-myc) in 
adult NIH Swiss mice.  DNA was amplified by PCR using 
Oligos610/511 for the 5' myc gene and Oligos513/515 for 
the 3' myc gene and Oligos509/512 for the 5' ras gene and 
Oligos514/515 for the 3' ras gene.   The PCR products were 
resolved by electrophoresis on a 1.8% agarose gel.  A. The 
5' myc and 3' myc gene. B. The 5' ras and 3' ras gene.  Lanes 
M; marker; lanes a: no DNA control; lanes b: positive 
controls pMSV-T24-H-ras or pMSV-c-myc; lanes c: D003-E 
cell line; lanes d: D003-E tumor; lanes e: D003-F cell line; 
lanes f: D003-F tumor. Int. J. Biol. Sci. 2010, 6 
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  In contrast to the finding with the cell lines es-
tablished from the tumors induced in adult mice, 
DNA from the four cell lines established from tumors 
induced in newborn mice with 
pMSV-T24-H-ras/MSV-c-myc (D004-B, D004-F, 
D004-I, D004-K) all yielded PCR-amplified products 
of the predicted size using the 5' or 3' myc primers and 
the 5' or 3' ras primers (Fig. 4A and B), demonstrating 
that all four of these cell lines contained both the 
T24-H-ras and the c-myc genes.   
 
 
 
Fig. 4. PCR analysis of DNA isolated from cell lines from 
tumors induced by the dual-expression plasmids 
(pMSV-T24-H-ras/MSV-c-myc) in newborn NIH Swiss mice.  
DNA was amplified by PCR using Oligos610/511 for the 5' 
myc gene and Oligos513/515 for the 3' myc gene and Oli-
gos509/512 for the 5' ras gene and Oligos514/515 for the 3' 
ras gene.  The PCR products were resolved by electro-
phoresis in a 1.8% agarose gel. A. The 5' myc and 3' myc 
gene. B. The 5' ras and 3' ras gene.  Lanes M; marker; lanes 
a: no DNA control; lanes b: positive controls 
pMSV-T24-H-ras or pMSV-c-myc; lanes c: D004-B; lanes d: 
D004-F; lanes e: D004-I; lanes f: D004-K. 
 
Expression of c-Myc and H-Ras proteins 
  If the c-myc and activated H-ras genes were in-
ducing the tumorigenic phenotype in mouse cells, 
then the oncoproteins from these genes should be 
expressed in the tumor-cell lines. The expression of 
the c-Myc and H-Ras proteins was assessed using 
Western analysis of lysates prepared from the tu-
mor-cell lines discussed above. 
 Expression of the c-Myc and H-Ras oncoproteins 
in cell lines established from tumors induced in adult 
NIH Swiss mice is shown in Fig. 5. The antibody to 
mouse c-Myc detected a protein of approximately 60 
kD (D003-A, D003-I, and D003-J; Fig. 5A, lanes c, e, 
and f); this is the expected size for the c-Myc protein. 
Conversely, those cell lines that did not express c-Myc 
(D003-F and D003-E; Fig. 5A, lanes d and g) were the 
cell lines whose DNA also did not have amplifiable 
c-myc sequences (Fig. 2A). The less intense band visi-
ble in the samples prepared from line D003-F (Fig. 5A, 
lane d) is likely due to the endogenous c-Myc protein, 
as samples prepared from NIH 3T3 cells had a band of 
similar intensity and size (Fig. 5A, lane b). A similar 
correlation was found for H-Ras expression, viz., the 
cell lines that expressed the approximately 21 kD 
protein (D003-A, D003-I, and D003-J; Fig. 5B, lanes c, 
e, and f) and those that did not (D003-F and D003-E; 
Fig. 5B, lanes d and g) were those cell lines whose 
DNA either did, or did not, contain H-ras DNA as 
measured by PCR amplification (Fig. 2B). The absence 
of c-Myc or H-Ras bands was not a consequence of 
protein not being loaded, since the same membranes 
were probed with anti-actin antibody and similar 
amounts of that protein were detected in all lanes (Fig. 
5C and D).  
 For the cell lines that were derived from tumors 
induced in newborn mice, all lines expressed both 
c-Myc and H-Ras proteins (Fig. 6A and B) as expected, 
since these lines contained both the c-myc and H-ras 
genes (Fig. 4A and B).  
Integration patterns of the plasmid DNA 
  The integration pattern of the oncogene-exp-
ression plasmid pMSV-T24-H-ras/MSV-c-myc pro-
vides information on the number of copies and the 
sites of integration; this information can be used to 
determine whether the tumors were clonal. If the tu-
mors were monoclonal, then a single cell would have 
been transformed, which would explain the low effi-
ciency of tumor induction by DNA. In contrast, if the 
tumor were oligoclonal or polyclonal, then the effi-
ciency of tumor induction would be correspondingly 
higher.  
 Southern hybridization was used to analyze the 
integration pattern of the oncogene-expression plas-
mid pMSV-T24-H-ras/MSV-c-myc. DNA prepared 
from the three PCR-positive cell lines derived from 
tumors induced in adult mice and the four cell lines 
derived from tumors induced in newborn mice was 
digested with BglII, an enzyme that cleaves 
pMSV-T24-H-ras/MSV-c-myc once. The digested 
DNAs were fractionated by electrophoresis on 1% 
agarose gels and the DNA was transferred to Hy-
bond-N+ membranes. One membrane was hybridized 
with a c-myc probe (Fig. 7A), while the other was hy-
bridized with an H-ras probe (Fig. 7B). The endogen-Int. J. Biol. Sci. 2010, 6 
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ous mouse c-myc gene was the only hybridizing band 
seen in NIH 3T3 DNA (Fig. 7A, lane b), and a corres-
ponding band was seen in all lanes (indicated by the 
arrow in Fig. 7A). Most of the DNAs prepared from 
tumor-cell lines from tumors induced in adult mice 
(Fig. 7A, lanes c, d, e) or in newborn mice (lanes f, g, i) 
had one or two additional c-myc-hybridizing bands, 
demonstrating that each of these tumors was likely 
derived from a single oncogenic event and that the 
tumors were clonal. The exception was tumor-cell line 
D004-I (Fig. 7, lane h), which was derived from a tu-
mor induced in newborn mice. This line had multiple 
copies of the c-myc plasmid sequences, and thus it is 
not possible to determine whether the original tumor 
was clonal.  
  With the H-ras probe, the endogenous mouse 
H-ras gene was less apparent in NIH 3T3 DNA (Fig. 
7B, lane b), presumably because the probe was pre-
pared from the human gene [32]. As seen with the 
analysis with the c-myc probe, in the analysis of the 
DNA from all but one line, the patterns of integration 
were simple, with one or two bands present. The ex-
ception was D004-I, whose DNA had multiple 
H-ras-hybridizing bands (Fig. 7B, lane h); DNA from 
this line also had multiple c-myc-hybridizing bands.  
  Because each of the tumor-cell lines had a dif-
ferent pattern of hybridization, the tumors were de-
rived from different oncogenic events. Because the 
patterns of hybridizing bands in the Southern blots 
were simple in all but one case, most of the tumors 
were likely to be clonal, a conclusion also reached in 
our earlier study [32].  
 
 
 
 
 
 
Fig. 5. Western blot analysis of the expression of c-Myc and H-Ras in lysates of tumor cell lines derived from tumors 
induced in adult NIH Swiss mice. Lysates (2.5 µg for H-Ras and 30 µg for c-Myc) prepared from cell lines established from 
tumors were fractionated by SDS-PAGE (4-20% gel) and transferred to a PVD membrane. A. Antibody 9402 to c-Myc. B. 
Antibody C-20 to H-Ras. Lanes a: marker; lanes b: NIH 3T3; lanes c: D003-A; lanes d: D003-F; lanes e: D003-I; lanes f: 
D003-J; lanes g: D003-E. C. and D. The PVD membranes were reacted with the anti-actin antibody SC-1616; a band mi-
grating at approximately 43 kD is seen in all lanes.  Int. J. Biol. Sci. 2010, 6 
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Fig. 6. Western analysis for the expression of c-Myc and H-Ras in lysates of tumor cell lines derived from tumors induced 
in newborn NIH Swiss mice. Lysates (2.5 µg for H-Ras and 30 µg for c-Myc) prepared from cell lines established from 
tumors were fractionated by SDS-PAGE (4-20% gel) and transferred to a PVD membrane. A. Antibody 9402 to c-Myc. B. 
Antibody C-20 to H-Ras. Lanes a: marker; lanes b: NIH 3T3; lanes c: D004-B; lanes d: D004-F; lanes e: D004-I; lanes f: 
D004-K. C. and D. The PVD membranes were reacted with the anti-actin antibody SC-1616; a band migrating at ap-
proximately 43 kD is seen in all lanes.  
 
 
 
Fig. 7. Southern blot analysis of the integration pattern of the oncogenes in tumor cell lines. Tumor-cell-line DNA (8 µg) 
was digested with BglII, fractionated by electrophoresis on a 1% agarose gel, and analyzed by Southern hybridization. A. myc 
probe; B. ras probe. Lanes a: DNA size marker 1 kb ladder; lanes b: NIH 3T3; lanes c: D003-A; lanes d: D003-I; lanes e: 
D003-J; lanes f: D004-B; lanes g: D004-F; lanes h: D004-I; lanes i: D004-K; lanes j: DNA size maker lambda HindIII. 
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Assessment of transfection facilitators 
 If DNA uptake were a limiting step for the con-
version of a normal mouse cell into a tumor cell, then 
increasing the efficiency of DNA uptake might in-
crease the overall efficiency of tumor induction. We 
tested eleven commercially available reagents that 
have been widely used to increase transfection effi-
ciency in vitro to determine if any of these reagents 
would increase the efficiency of tumor formation in 
vivo. These compounds represent most of the different 
types of transfection facilitators: liposomal (Lipofec-
tamine, DMRIE-C, DOTAP, DOSPER, FuGene HD, 
and Transfectol); cationic liposomal (Effectene); ca-
tionic polymer (in vivo-JetPEI); polyamidoamine 
dendrimer (SuperFect and PolyFect); and a DNase 
inhibitor (aurintricarboxylic acid). Several of these 
facilitators had been used in animals to enhance the 
immunogenicity of DNA vaccines.  
  Because the total volume that we could safely 
inoculate into newborn mice was 50 µL, and because 
we wanted to use the ratio of facilitator to DNA rec-
ommended by the manufacturers to optimize the in 
vitro activity for their products, we were restricted to 2 
µg of the plasmid pMSV-T24-H-ras/MSV-c-myc. DNA 
and facilitator were mixed, and each complex was 
inoculated via the subcutaneous route into newborn 
NIH Swiss mice. No tumors were found with any of 
the inoculations that included a transfection facilita-
tor; one tumor was observed when DNA was inocu-
lated with the DNase inhibitor aurintricarboxylic acid.   
  One possibility for this result was that the 
transfection facilitators stimulated the cellular im-
mune system resulting in rejection of the tumor. In 
this case, then transfection facilitators might be ex-
pected to have activity in mice defective in cellular 
immunity. We assessed this possibility by testing a 
number of the facilitators in newborn athymic nude 
mice, because these animals have a defect in T-cell 
function. Two micrograms of 
pMSV-T24-H-ras/MSV-c-myc, either alone or com-
plexed with DMRIE-C, in vivo-JetPEI, or SuperFect 
were inoculated into newborn athymic nude mice 
between 1 and 3 days after birth. Because each litter of 
the athymic nude mouse has pups that can be nude 
(T-cell defective) or haired (immune competent), the 
experiment had an internal control for whether the 
immune system played a role. The results showed 
that none of the facilitators increased the tumor inci-
dence and that the nude mice and their haired litter-
mates had comparable tumor incidences, indicating 
that tumor suppression by an active T-cell system did 
not explain the lack of activity of the transfection faci-
litators.  
Discussion 
  Our previous experiments had shown that two 
cooperating oncogenes are needed to induce tumors 
in vivo. The results we present here show that, as ex-
pected, having both oncogenes on the same plasmid 
induces tumors more efficiently than having the two 
cooperating oncogenes on separate plasmids. The 
lowest amount of the dual-expression plasmid 
pMSV-T24-H-ras/MSV-c-myc that was able to induce 
tumors in newborn NIH Swiss mice was 1 µg. With 
adult mice, the lowest amount was 5 µg. This result 
agrees with our earlier finding with the separate ex-
pression plasmids [32], where newborn mice were 
found to be more sensitive to DNA-mediated tumor 
induction than adult mice.    
  Although the incidence of tumors induced by 
the three versions of the dual-expression plasmid 
pMSV-T24-H-ras/MSV-c-myc generally reflected the 
amount of DNA inoculated, there was no strict 
dose-response relationship, a result that was probably 
due to the relatively low number of animals used per 
group. This conclusion is supported if all three ver-
sions of the pMSV-T24-H-ras/MSV-c-myc plasmid are 
considered to be functionally indistinguishable (their 
in vitro transformation activities are the same) and the 
results for each DNA dose in Table 1 are combined. In 
this case, the incidence becomes: 20% for 20 µg, 21% 
for 10 µg, 13% for 5 µg, and 0% for 1 µg in the adult 
mouse, and 77% for 20 µg, 27% for 10 µg, 36% for 5 µg, 
and 7% for 1 µg in the newborn mouse. While there is 
still some variability, there is evidence of a 
dose-response relationship. Additional studies with 
larger numbers of mice are planned to address this 
experimental variability.  
  Establishing the clonality of the tumors was 
considered to be important. If the tumors were po-
lyclonal, then they would be derived from the trans-
formation of multiple normal mouse cells, and thus 
the efficiency of tumor induction by DNA would be 
higher than if the tumors were monoclonal and de-
rived from a single cell transformed by DNA. With 
one possible exception, the integration patterns of the 
plasmid DNA in the tumors were consistent with a 
single cell being converted into a tumor cell. The ex-
ception was the D004-I (Fig. 7A and B, lanes h), where 
the Southern analysis showed multiple BglII frag-
ments containing T24-H-ras or c-myc sequences, indi-
cating that multiple plasmid sequences were taken up 
and integrated in cells in the tumor. Whether the on-
cogenes in D004-I were taken up by a single cell, in 
which case the tumor would be clonal, or by multiple 
cells, in which case the tumor would not be clonal, 
remains to be determined. In our earlier study [32], a Int. J. Biol. Sci. 2010, 6 
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tumor-cell line whose DNA gave rise to multiple re-
striction fragments that hybridized to the ras and myc 
probes was shown, by single-cell cloning, to be clonal.  
 This conclusion, that the tumors were mostly, if 
not always, clonal would only be true if there were no 
bias in which of the cells in the tumor gave rise to the 
established cell lines in culture. While the tumors 
were not analyzed in this study, we have shown in 
other studies that oncogene-containing cells in tu-
mor-cell lines accurately reflect the population of on-
cogene-containing cells in the original tumors (un-
published observations).  
 One of the important practical findings from this 
study was that there could have been a selective loss 
of tumor cells when the tumor tissue was dispersed 
by trypsin digestion, thus resulting in the outgrowth 
of normal cells and the loss of tumor cells, as seen 
with two lines established from tumors induced in 
adult mice (Fig. 2). Whether tumor cells in these tu-
mors are more sensitive to trypsin digestion than 
normal untransformed cells is not known, but we 
have recently found that cutting up the tumors into 
small pieces and allowing tumor cells to grow out 
from these explants in culture has resulted in a higher 
success rate in establishing tumor-cell lines.  
  An unexpected finding was that reagents that 
increase DNA uptake in vitro did not increase the ef-
ficiency of tumor induction DNA in vivo. In fact, the 
transfection facilitators tested appeared to have a 
negative effect. One possible explanation for this 
finding was that the facilitators stimulated the im-
mune system and this immune activation caused a 
rejection of the tumor in the mouse. Because the cel-
lular arm of the immune system is believed to be in-
volved in tumor rejection, we assessed whether 
transfection facilitators would be effective in a mouse 
strain that is defective in T-cell function, the nude 
mouse. Although the numbers were small, no differ-
ences were found in the efficiency of DNA-induced 
tumor formation between the nude mice and their 
immune-competent littermates. This could indicate 
either that some part of the immune system other than 
the cellular arm is being stimulated or that DNA up-
take is not limiting. Additional experiments will be 
necessary to explain the lack of activity of the trans-
fection reagents in DNA-induced tumor formation.  
  The DNA oncogenicity assay described in this 
paper might provide a new way of measuring the 
activity of cellular or viral oncogenes in vivo without 
having to create cell lines expressing the oncogenes 
and then testing the tumorigenicity of these cells in 
either syngeneic animals or immune-deficient ani-
mals. For example, transfection of both activated 
H-ras and c-myc into normal rodent fibroblasts cells 
can convert these cells into cells that can form tumors 
in vivo [35-37]. However, direct inoculation of onco-
genes into animals would circumvent the in vitro step, 
potentially revealing hitherto unknown activities of 
these oncogenes. Direct inoculation of oncogenes 
might also be used to evaluate potential differences in 
the induction of tumors by DNA in vivo compared 
with the formation of tumors by the injection of cells 
transformed in vitro.  
  This study confirms results of our earlier expe-
riments showing that activated oncogenes from 
neoplastic cells are capable of inducing normal cells to 
become tumorigenic after direct injection into an an-
imal [32], a finding that argues that the potential risk 
from the residual DNA in vaccines produced in 
neoplastic cells can no longer be considered hypo-
thetical. However, because of the relative sizes of the 
oncogene expression plasmid and the mammalian 
genome, if 1 µg of the plasmid induces tumors, then 
100 µg to 1 mg of mammalian DNA would be re-
quired. We are currently evaluating different strains 
of mice, such as mice with various degrees of immune 
deficiencies and mice predisposed to tumor devel-
opment in response to carcinogens, for their sensitiv-
ity to DNA oncogenic activity in order to optimize 
assay sensitivity and more clearly define levels of risk 
posed by residual DNA in vaccines.  
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